Basilea Pharmaceutica Ltd (PK5)
FSX
Closed
Oct 7, 2026
Day's Range
69.7052 wk Range
47.80Overview - PK5 - Basilea Pharmaceutica Ltd
Key Statistics
Valuation
Enterprise Value
864.32M
P/E (Trailing)
‪17.13‬
Price / Sales (TTM)
‪3.65‬
Price / Book
‪5.26‬
EV / EBITDA
‪13.39‬
Profitability
Profit Margin
‪21.17%‬
Operating Margin
‪26.89%‬
Return on Assets
‪13.68%‬
Return on Equity
‪39.45%‬
Ownership
Shares Outstanding
12.37M
Float
11.31M
Held by Insiders
‪0.61%‬
Held by Institutions
‪31.42%‬
Price stats
Beta
‪0.43‬
50-Day Avg
‪63.46‬
200-Day Avg
‪59.43‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - PK5 - Basilea Pharmaceutica Ltd
Peers - PK5 - Basilea Pharmaceutica Ltd
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- PK5FSXBasilea Pharmaceutica Ltd904.60MMarket Cap+34.45%52-week change17.14P/E (Trailing)‪21.17%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- 0QFFSXModerna Inc.69.12BMarket Cap+87.76%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.53.43BMarket Cap+42.53%52-week change179.66P/E (Trailing)‪30.74%‬Profit Margin
- 1AEFSXargenx SE52.63BMarket Cap+28.29%52-week change36.62P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt50.36BMarket Cap+25.47%52-week change34.88P/E (Trailing)‪32.26%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.58BMarket Cap+78.78%52-week change-29.47P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - PK5 - Basilea Pharmaceutica Ltd
About
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company headquartered in Allschwil, Switzerland, founded in 2000 as a spin-off from F. Hoffmann-La Roche. With approximately 150 employees, it focuses on discovering, developing, and commercializing innovative anti-infective drugs to address severe…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
